Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMBARK

Bayer symbol

Bayer preps filings for new prostate cancer drug

If approved, will challenge Xtandi and Erleada

- PMLiVE

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

- PMLiVE

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

Findings demonstrated a 71% reduction in cancer spreading and death

- PMLiVE

Astellas strengthens US and Canadian leadership team

Steve Sabus, Lynn Gerber and Kevin O’Keefe are promoted to new roles

- PMLiVE

Astellas promotes Anthony Fiordaliso to VP, Americas finance

He first joined the pharma firm in 2010 from Schering-Plough

- PMLiVE

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

FDA fast-tracks Astellas’ Rydapt rival

AML treatment gilteritinib is currently involved in four phase III trials

- PMLiVE

Astellas extends phase III programme for Rydapt rival gilteritinib

Japanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment

- PMLiVE

Xtandi slowdown weighs on Pfizer, but CEO won’t move on M&A

Investors call on the pharma giant to consider a large merger or acquisition deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links